We provide you with 20 years of free, institutional-grade data for AMRN stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of AMRN. Explore the full financial landscape of AMRN stock.
Total insider purchase within 3 month on this page: $0
Total insider selling within 3 month on this page: -$0
| Name | Action | Shares | Avg Price | Amount | Reported Date |
|---|---|---|---|---|---|
| Holt Patrick | Open Market Purchase | 14,426 | $1.09 | 2024-01-24 | |
| Berg Aaron | Sale | -28,214 | $0.97 | $27,368 | 2024-01-12 |
| Berg Aaron | Derivatives Exercise | 51,500 | 2024-01-12 | ||
| Berg Aaron | RSU | 51,500 | 2024-01-12 | ||
| Ketchum Steven B | Sale | -28,270 | $0.97 | $27,422 | 2024-01-12 |
| Ketchum Steven B | Derivatives Exercise | 51,500 | 2024-01-12 | ||
| Ketchum Steven B | RSU | 51,500 | 2024-01-12 | ||
| Reilly Thomas Charles | Sale | -28,325 | $0.97 | $27,475 | 2024-01-12 |
| Reilly Thomas Charles | Derivatives Exercise | 51,500 | 2024-01-12 | ||
| Reilly Thomas Charles | RSU | 51,500 | 2024-01-12 | ||
| Ketchum Steven B | Sale | -7,730 | $0.87 | $6,725 | 2024-01-08 |
| Ketchum Steven B | Derivatives Exercise | 14,566 | 2024-01-08 | ||
| Ketchum Steven B | RSU | 14,566 | 2024-01-08 | ||
| Berg Aaron | Sale | -15,460 | $0.87 | $13,450 | 2024-01-08 |
| Berg Aaron | Derivatives Exercise | 29,133 | 2024-01-08 | ||
| Berg Aaron | RSU | 29,133 | 2024-01-08 | ||
| Ketchum Steven B | Sale | 23,525 | $0.87 | 2024-01-02 | |
| Ketchum Steven B | Derivatives Exercise | 47,766 | 2024-01-02 | ||
| Ketchum Steven B | RSU | -47,766 | 2024-01-02 | ||
| Berg Aaron | Sale | -23,525 | $0.87 | $20,467 | 2024-01-02 |
| Berg Aaron | Derivatives Exercise | 47,766 | 2024-01-02 | ||
| Berg Aaron | RSU | -47,766 | 2024-01-02 | ||
| Ketchum Steven B | Sale | -34,131 | $0.79 | $26,963 | 2023-12-14 |
| Holt Patrick | Open Market Purchase | 300,000 | $1.02 | 2023-08-16 | |
| Berg Aaron | Sale | -11,763 | $1.19 | $13,998 | 2023-08-02 |
| Berg Aaron | Derivatives Exercise | 23,883 | 2023-08-02 | ||
| Berg Aaron | RSU | -23,883 | 2023-08-02 | ||
| Ketchum Steven B | Sale | -11,763 | $1.19 | $13,998 | 2023-08-02 |
| Ketchum Steven B | Derivatives Exercise | 23,883 | 2023-08-02 | ||
| Ketchum Steven B | RSU | -23,883 | 2023-08-02 | ||
| Reilly Thomas Charles | Sale | -8,209 | $1.19 | $9,769 | 2023-07-05 |
| Reilly Thomas Charles | Derivatives Exercise | 16,667 | 2023-07-05 | ||
| Reilly Thomas Charles | Sale | -16,417 | $1.19 | $19,536 | 2023-06-22 |
| Reilly Thomas Charles | Derivatives Exercise | 33,334 | 2023-06-22 | ||
| Sterling Louis III | Initial | 2023-03-10 | |||
| Berg Aaron | Sale | -7,718 | $2.03 | $15,668 | 2023-03-08 |
| Berg Aaron | Derivatives Exercise | 16,333 | 2023-03-08 | ||
| Ketchum Steven B | Sale | -7,718 | $2.03 | $15,668 | 2023-03-08 |
| Ketchum Steven B | Derivatives Exercise | 16,333 | 2023-03-08 | ||
| Mikhail Karim | Grant, award...etc | 33,334 | 2023-02-23 | ||
| Mikhail Karim | Sale | -72,311 | $1.86 | $134,498 | 2023-02-23 |
| Mikhail Karim | Derivatives Exercise | 207,700 | 2023-02-23 | ||
| Ketchum Steven B | Grant, award...etc | -29,134 | 2023-02-23 | ||
| Ketchum Steven B | Sale | -28,226 | $1.86 | $52,500 | 2023-02-23 |
| Ketchum Steven B | Derivatives Exercise | 34,567 | 2023-02-23 | ||
| WOLD OLSEN PER | Derivatives Exercise | 22,027 | 2023-02-23 | ||
| Berg Aaron | Grant, award...etc | 58,267 | 2023-02-23 | ||
| Berg Aaron | Sale | -41,869 | $1.86 | $77,876 | 2023-02-23 |
| Berg Aaron | Derivatives Exercise | 34,567 | 2023-02-23 |
The information provided in this report about AMRN stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Amarin Corporation plc(NASDAQ:AMRN) 
Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States. Its lead product is VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing t...
Website: http://www.amarincorp.com
Founded: 1989
Full Time Employees: 965
Sector: Healthcare
Industry: Biotechnology